You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Her2 amplified solid tumors

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

HER2 Mutation-Related Tumors, HER2 Amplified Solid Tumors Trial in Miami Beach, Kansas City (ARX788)

Withdrawn
  • HER2 Mutation-Related Tumors
  • HER2 Amplified Solid Tumors
  • Miami Beach, Florida
  • +1 more
Apr 22, 2022

HER2 Mutation-Related Tumors, HER2 Amplification Trial (ARX788)

Not yet recruiting
  • HER2 Mutation-Related Tumors
  • HER2 Amplification
  • (no location specified)
Aug 23, 2021

Solid Tumor Trial (Pyrotinib Maleate, standard regimen)

Not yet recruiting
  • Solid Tumor
  • Pyrotinib Maleate
  • standard regimen
  • (no location specified)
Mar 9, 2022

Solid Tumor, EGFR Amplification Trial in Tianjin (Nimotuzumab)

Recruiting
  • Solid Tumor
  • EGFR Amplification
  • Tianjin, Tianjin, China
    Tianjin Medical University Second Hospital
Aug 28, 2023

HER2-positive Advanced Solid Tumors Trial in Shanghai (DP303c)

Recruiting
  • HER2-positive Advanced Solid Tumors
  • Shanghai, Shanghai, China
    Fudan University Shanghai Cancer Center
Apr 10, 2023

Solid Tumor Trial in Shenyang (Intravenous infusion anti-HER2-CAR-T cell)

Not yet recruiting
  • Solid Tumor
  • Intravenous infusion anti-HER2-CAR-T cell
  • Shenyang, Liaoning, China
    Phase I Clinical Trials Center Of The First Hospital of China Me
Oct 30, 2023

HER-2 Positive Advanced Solid Tumors Trial (D3L-001)

Not yet recruiting
  • HER-2 Positive Advanced Solid Tumors
  • D3L-001
  • (no location specified)
Jul 20, 2023

Her2-positive/Low-expression Urinary and Digestive Tract Tumors Trial in Beijing (BL-M07D1)

Not yet recruiting
  • Her2-positive/Low-expression Urinary and Digestive Tract Tumors
  • Beijing, Beijing, China
    Cancer Hospital, Chinese Academy of Medical Sciences
Sep 8, 2023

HER2 Positive Advanced Solid Tumors Trial (HypoSti.CAR-HER2 T cells, Albumin-bound paclitaxel, Cyclophosphamide)

Not yet recruiting
  • HER2 Positive Advanced Solid Tumors
  • HypoSti.CAR-HER2 T cells
  • +2 more
  • (no location specified)
Jan 12, 2023

Solid Tumor Trial (Disitamab vedotin)

Not yet recruiting
  • Solid Tumor
  • Disitamab vedotin
  • (no location specified)
Jul 10, 2023

HER2+ Advanced Breast Cancer, Other Solid Tumors Trial (ADCC-R-Epo-R T-cells + Trastuzumab, Erythropoietin beta, Fludarabine and

Not yet recruiting
  • HER2+ Advanced Breast Cancer
  • Other Solid Tumors
  • ADCC-R-Epo-R T-cells + Trastuzumab
  • +2 more
  • (no location specified)
Aug 31, 2023

Solid Tumor Trial (HER2-E-CART cells)

Not yet recruiting
  • Solid Tumor
  • HER2-E-CART cells
  • (no location specified)
Feb 16, 2023

Carcinoma, Squamous Cell of Head and Neck, NSCLC, Ovarian Tumors Trial (disitamab vedotin)

Not yet recruiting
  • Carcinoma, Squamous Cell of Head and Neck
  • +3 more
  • disitamab vedotin
  • (no location specified)
Aug 15, 2023

HER2-overexpressed Advanced Solid Tumors After Progression of

Not yet recruiting
  • HER2
  • +3 more
  • Disitamab Vedotin
  • Beijing, Beijing, China
    Beijing Cancer Hospital
Dec 14, 2022

NSCLC Trial in Beijing (Pyrotinib)

Recruiting
  • Non-small Cell Lung Cancer
  • Beijing, Beijing, China
    Peking Union Medical College
Feb 20, 2023

HER2 Positive Solid Tumors Trial in Australia, Korea, Republic of, United States (SBT6050, pembrolizumab, Cemiplimab)

Active, not recruiting
  • HER2 Positive Solid Tumors
  • Boston, Massachusetts
  • +11 more
Jun 27, 2022

HER2-positive Breast Cancer, HER2-positive Gastric Cancer, HER2-positive NSCLC Trial (XMT-2056)

Not yet recruiting
  • HER2-positive Breast Cancer
  • +4 more
  • (no location specified)
Aug 23, 2022

Advanced Solid Tumor, Advanced Lung Cancer, Advanced Gastric Carcinoma Trial in Beijing, Shanghai (IMM2902)

Recruiting
  • Advanced Solid Tumor
  • +3 more
  • Beijing, China
  • +1 more
Apr 6, 2023

Esophageal Tumors, Gastric Tumors Malignant, Breast Cancer Trial in Stockholm ([68Ga]Ga-ABY-025 PET, Biopsy and analysis of HER2

Recruiting
  • Esophageal Neoplasms
  • +3 more
  • [68Ga]Ga-ABY-025 PET
  • Biopsy and analysis of HER2 expression
  • Stockholm, Sweden
    Department of Radiation Physics and Nuclear Medicine, Karolinska
Nov 25, 2022

Advanced Solid Tumor, Advanced Breast Cancer, Metastatic Breast Cancer Trial (BGB-43395, Fulvestrant, Letrozole)

Not yet recruiting
  • Advanced Solid Tumor
  • +8 more
  • (no location specified)
Nov 13, 2023

Breast Cancer, Gastric Cancer, Gastroesophageal-junction Cancer Trial in Australia (IKS014)

Not yet recruiting
  • Breast Cancer
  • +2 more
  • Concord, New South Wales, Australia
  • +4 more
May 30, 2023

HER-2 Gene Amplification, HER2-positive Gastric Cancer, HER2-positive Breast Cancer Trial in United States (chimeric antigen

Recruiting
  • HER-2 Gene Amplification
  • +4 more
  • chimeric antigen receptor (CAR) T cell therapy
  • Duarte, California
  • +6 more
Aug 10, 2022

HER2-expressing Advanced Solid Tumors Trial (SHR-A1811 combined with Pyrotinib., SHR-A1811 combined with other antitumor

Not yet recruiting
  • HER2-expressing Advanced Solid Tumors
  • SHR-A1811 combined with Pyrotinib.
  • SHR-A1811 combined with other antitumor therapies
  • (no location specified)
Aug 28, 2023

Advanced Solid Tumors Trial in Tianjin (KM501)

Not yet recruiting
  • Advanced Solid Tumors
  • Tianjin, Tianjin, China
    Tianjin Cancer Hospital
Apr 5, 2023

Tumors, Ovarian Cancer, Breast Cancer Trial in Houston (ZN-c3, Bevacizumab, Pembrolizumab)

Not yet recruiting
  • Tumors
  • +4 more
  • Houston, Texas
    MD Anderson Cancer Center
Jun 20, 2022